ArticleAdvances in radiation oncology2026
Low Incidence of New-Onset Hypopituitarism After High-Precision Stereotactic Radiation Therapy of Sellar and Perisellar Lesions.
Article in Advances in radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Radiation therapy-induced hypopituitarism (RIH) is a common complication of radiation therapy, even if the pituitary gland is not the primary target but lies within the irradiation field. This study aimed to investigate the impact of high-precision radiation therapy for benign sellar and perisellar tumors, using radiosurgery or fractionated/hypofractionated stereotactic radiation therapy with the Novalis System (Brainlab), on functional pituitary integrity. Methods and Materials: Fifty-six patients who underwent stereotactic radiation therapy for meningiomas of the sellar or perisellar region of the skull base (n = 36) or pituitary adenomas (n = 20) were recruited between 2013 and 2021 at a single radiooncologic clinic. Fractionated stereotactic radiation therapy was the main irradiation technique (n = 42), followed by hypofractionated stereotactic radiation therapy (n = 4) and stereotactic radiosurgery (n = 10). Irradiation data were assessed retrospectively, and radiation exposure to the pituitary was measured by dose-volume histograms. Each patient received an endocrine diagnostic workup, including a comprehensive functional pituitary analysis. Results: The median age was 57 years (IQR, 50-63 years), and 42 of 56 patients (75%) were women. RIH was present in 10.7% (n = 6) of patients after a median follow-up of 83.5 months. Gonadotroph function was affected in 7.1% (n = 4) of patients, followed by corticotroph, thyreotroph, somatotroph, and lactotroph function, each at 1.8% (n = 1). Only 1 patient received hormonal replacement for RIH at the study visit. Conclusions: Awareness of radiation therapy-induced damage to the pituitary gland is essential in the follow-up after radiation therapy of the surrounding structures of the hypothalamic-pituitary axis. High-precision fractionated stereotactic radiation therapy holds a low risk of RIH after irradiation of benign lesions of the sellar and perisellar region.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.